Detalhe da pesquisa
1.
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
N Engl J Med
; 390(13): 1186-1195, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598573
2.
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis
; 80(8): 1004-1013, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906853
3.
Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.
Rheumatology (Oxford)
; 57(8): 1390-1399, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718421
4.
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 76(8): 1340-1347, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28130206
5.
Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study.
BMC Musculoskelet Disord
; 17: 293, 2016 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27424036
6.
Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial.
Rheumatol Ther
; 10(4): 1001-1020, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37331992
7.
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib.
Ther Adv Musculoskelet Dis
; 15: 1759720X221149965, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36777695
8.
Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
BMC Rheumatol
; 6(1): 68, 2022 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36045453
9.
Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
RMD Open
; 8(2)2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654457
10.
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
Rheumatol Ther
; 9(2): 411-433, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921355
11.
Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
Lancet Rheumatol
; 3(4): e270-e283, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38279411
12.
Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Lancet Rheumatol
; 3(1): e28-e39, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38273637
13.
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Rheumatol Ther
; 7(3): 553-580, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32506317
14.
In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor.
Clin Pharmacol Drug Dev
; 7(3): 244-255, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29112329
15.
Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
Int J Rheum Dis
; 20(8): 960-970, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28328159
16.
Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children.
Pediatr Infect Dis J
; 22(4): 315-23, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12690270
17.
Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Pediatr Infect Dis J
; 22(9 Suppl): S178-85, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-14520144
18.
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Arthritis Res Ther
; 14(1): R11, 2012 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22251436